Greg Kennelty


Individualized Treatment Needed for Patients With NRAS-Mutated mCRC

January 15th 2017

Activating, hotspot mutations in the NRAS gene occur in a small subset of patients with metastatic colorectal cancer. These mutations are now being identified in routine clinical practice by extended RAS genotyping.

Nab-Paclitaxel Proves More Beneficial Than Paclitaxel in Some Subsets of Breast Cancer

January 7th 2017

Nab-paclitaxel provides more benefits than paclitaxel for certain subsets of patients with breast cancer.

Lapatinib Plus Whole-Brain Radiotherapy May Control Brain Metastases in HER2+ Breast Cancer

January 4th 2017

An investigation of the tyrosine kinase inhibitor lapatinib plus whole-brain radiotherapy has entered into a phase II trial in the treatment of patients with brain metastases from HER2-positive breast cancer.

Expert Sheds Light on Efficacy of Dual HER2-Directed Therapy

November 15th 2016

Dual HER2-directed therapy has demonstrated promising efficacy as a treatment approach for patients with breast cancer. Still, there remains a need for further research pertaining to therapies for HER2-positive patients who do do not meet the current criteria for this neoadjuvant regimen.

Expert Discusses Impact of Atezolizumab in Advanced Bladder Cancer

September 15th 2016

The PD-L1 inhibitor atezolizumab has been found to be non-toxic and has demonstrated a major survival advantage in patients with metastatic urothelial bladder cancer.

Biology of Triple-Negative Breast Cancer Crucial for Most Effective Treatment

September 15th 2016

It is important to achieve a complete and thorough understanding of triple-negative breast cancer in order to most effectively treat patients.

Expert Sheds Light on Important Variables in Preventive Surgery in Ovarian Cancer

September 14th 2016

Several variables are important to consider when undergoing preventive surgery for ovarian cancer, including familial history and age.

Expert Highlights Potential of Immunotherapy in Gastric Cancer

August 29th 2016

Zev Wainberg, MD, discusses a plethora of immunotherapy agents, such as pembrolizumab (Keytruda), durvalumab, avelumab, and apatinib, for the treatment of patients with gastric cancer, as well as a number of ongoing clinical trials in this space.

Expert Explains Significance of Early Tumor Shrinkage in Metastatic Colorectal Cancer

August 10th 2016

Volker Heinemann, MD, PhD, discusses the connection between early tumor shrinkage and overall survival, depth of response, and what it could mean for the future of metastatic colorectal cancer treatment.

Expert Hopeful About Emerging Options in Pancreatic Cancer Care

August 8th 2016

Eileen O'Reilly, MD, discusses optimal sequencing of therapies for patients with pancreatic cancer, what potential immunotherapy has in the field, and whether the microenvironments and immune privilege within the malignancy should be understood.

Grothey Gives Insight on Nintedanib, Immunotherapy Activity in CRC

July 28th 2016

Axel Grothey, MD, discusses both the LUME-1 and LUME-2 trials, the differences between left and right tumors in colorectal cancer, and how that information could potentially be used in diagnosis and treatment.

Expert Shares Obstacles With Neoadjuvant Chemo in GEJ and Esophageal Cancers

July 28th 2016

David Ilson, MD, PhD, discusses pre-operative chemotherapy alone versus chemotherapy plus radiation therapy in patients with esophageal and gastroesophageal-junction cancers, and how data points to the latter being the better choice.

Early Assessment of BRCA Status Key in Ovarian Cancer, Two Experts Agree

July 19th 2016

Robert Coleman, MD, and Leslie Randall, MD, provide further insight on the importance of BRCA testing.

Expert Shares Potential of Durvalumab in Patients With Urothelial Bladder Cancer

July 15th 2016

Saeed Rafii, MD, PhD, MRCP, discusses the PD-L1 inhibitor durvalumab, the encouraging findings of it in Study 1108, and the evolving landscape of bladder cancer.

Risks for Breast, Ovarian Cancers Could Be Found With Multigene Panel Testing

July 14th 2016

Allison W. Kurian, MD, MSc, discusses 2 clinical trials utilizing multigene panels to uncover previously undetected risks in patients with breast and ovarian cancer.

CDK4/6 Inhibitor Shows Promise as Single Agent in HR+ Breast Cancer

July 6th 2016

Maura Dickler, MD, discusses findings from the recent phase II study exploring abemaciclib as a single agent in patients with HR-positive breast cancer, along with an upcoming phase III trial looking at combination strategies.

Expert Shares Insight on Improved DFS With TaxAC in HER2-Negative Breast Cancer

July 5th 2016

Joanne L. Blum, MD, PhD, discusses the design and phase III results from the ABC trials, and what impact the encouraging findings could have in patients with HER2-negative breast cancer.

Expert Sheds Light on Promising Immunotherapy Combo Data in mCRC

June 23rd 2016

Michael J. Overman, MD, discusses the findings of the phase II CheckMate-142 study, which examined nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with high microsatellite instability colorectal cancer.

Efforts Continue to Optimize Ibrutinib in CLL

June 2nd 2016

Jennifer Brown, MD, discusses the findings and impact of the RESONATE and RESONATE-2 trials, as well as the role of ibrutinib in older and younger patients with chronic lymphocytic leukemia in both the frontline and relapsed settings.

Expert Shares Significance of Approved Agents in CRC

June 2nd 2016

Tanios Bekaii-Saab, MD, discusses the use of both regorafenib and TAS-102, as well as the potential role immunotherapy could have within colorectal cancer.